GB Patent

GB2148299B — Antibody compositions of therapeutic agents having an extended serum half-life

Assigned to Hybritech Inc · Expires 1988-01-06 · 38y expired

What this patent protects

A therapeutic agent e.g. alpha-interferon, complexes with an antibody without impairing the activity. The antibody can be a monoclonal antibody. The serum half-life of the therapeutic agent administered as the complex is substantially increased when compared to that of the agent …

USPTO Abstract

A therapeutic agent e.g. alpha-interferon, complexes with an antibody without impairing the activity. The antibody can be a monoclonal antibody. The serum half-life of the therapeutic agent administered as the complex is substantially increased when compared to that of the agent administered alone.

Drugs covered by this patent

Patent Metadata

Patent number
GB2148299B
Jurisdiction
GB
Classification
Expires
1988-01-06
Drug substance claim
No
Drug product claim
No
Assignee
Hybritech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.